Josh Brown: Biotech growth stocks immune to disruption risk [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
and AbbVie with broad product portfolios and multi-year pipeline replacements can navigate structural revenue erosion that slower innovators cannot survive. The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC's Halftime Report this week about large-cap biotech: "These are growth stocks where you don't have to worry about disruption. They're breaking out." His reasoning is that companies dealing in molecules, proteins, and clinical trials occupy a fundamentally different risk category than software or media. AI can disrupt a platform overnight; it cannot disrupt a decade-long drug approval process. Large-cap biotech does enjoy a structural insulation from the overnight platform disruption that has hollowed out tech companies. But the sector faces its own slow-motion disruption forces — patent cliffs, biosimilar competition, and government drug pricing reform — that ar
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Viokace (AbbVie) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]Yahoo! Finance
- AbbVie (ABBV) had its "buy" rating reaffirmed by Guggenheim.MarketBeat
- RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages [Yahoo! Finance]Yahoo! Finance
- Market Downturn: 2 Stocks to Buy and Hold Through Any Storm [Yahoo! Finance]Yahoo! Finance
- AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
ABBV
Earnings
- 2/4/26 - Miss
ABBV
Sec Filings
- 3/11/26 - Form 4/A
- 3/9/26 - Form PRE
- 3/6/26 - Form 4
- ABBV's page on the SEC website